生物活性

• 描述CMX001 was developed as an orally active, lipophilic form of cidofovir (CDV) and has enhanced activity in vitro and in vivo compared to CDV against certain herpesviruses, adenoviruses and orthopoxviruses.
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT03339401	Adenovirus	Phase 2	Recruiting	February 21, 2020	United States, California ... more >> Children's Hospital of Los Angeles Recruiting Los Angeles, California, United States, 90027 Principal Investigator: Hisham Abdel-Azim, MD          University of California San Francisco Recruiting San Francisco, California, United States, 94143 Principal Investigator: Jasmeen Dara, MD          United States, Illinois University of Chicago Recruiting Chicago, Illinois, United States, 60637 Principal Investigator: Kathleen Mullane, DO          United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Principal Investigator: Genovefa Papanicolaou, MD          United States, North Carolina Duke University Medical Center Not yet recruiting Durham, North Carolina, United States, 27705 Principal Investigator: Vinod Prasad, MD          United States, Ohio Cincinnati Childrens Hospital Medical Center Recruiting Cincinnati, Ohio, United States, 45229 Principal Investigator: Michael Grimley, MD          United States, Pennsylvania Children's Hospital of Philadelphia Not yet recruiting Philadelphia, Pennsylvania, United States, 19104 Principal Investigator: Nancy Bunin, MD          United States, Tennessee St. Jude Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Principal Investigator: Gabriela Maron, MD          United States, Washington University of Washington-Seattle Childrens Hospital Recruiting Seattle, Washington, United States, 98105 Principal Investigator: Janet Englund, MD          France Hopital Necker-Enfants Malades Recruiting Paris, France, 75015 Principal Investigator: Stephane Blanche          Hopital Universitaire Robert Debre Recruiting Paris, France, 75019 Principal Investigator: Jean-Hugues Dalle          Ireland Our Lady's Children Hospital Recruiting Dublin, Ireland, D12 N512 Principal Investigator: Andrea Malone, MD          Spain Hospital Sant Joan de Deu Recruiting Esplugues De Llobregat, Barcelona, Spain, 08950 Principal Investigator: Claudia Fortuny Guasch          Hospital Infantil Universitario Nino Jesus Recruiting Madrid, Spain, 28009 Principal Investigator: Miguel Diaz Perez          United Kingdom Royal Marsden Hospital Recruiting Sutton, Surrey, United Kingdom, SM2 5PT Principal Investigator: Mark Ethell          Leeds Children's Hospital Recruiting Leeds, West Yorkshire, United Kingdom, LS1 3EX Principal Investigator: Rebecca James, MD          Bristol Royal Hospital for Children Recruiting Bristol, United Kingdom, BS2 8BJ Principal Investigator: Ponni Sivaprakasam, MD          Royal Hospital for Sick Children Recruiting Glasgow, United Kingdom, G51 4TF Principal Investigator: Brenda Gibson          University College London Hospital Recruiting London, United Kingdom, NW1 2BU Principal Investigator: Rachael Hough, MD          St Marys Hospital Recruiting London, United Kingdom, W2 1NY Principal Investigator: Jesus de la Fuente Pereda          Great Ormond Street Hospital for Children Recruiting London, United Kingdom, WCIN 3JH Principal Investigator: Kanchan Rao          Royal Manchester Childrens Hospital Recruiting Manchester, United Kingdom, M13 9WL Principal Investigator: Robert Wynn          Sheffield Children's Hospital Recruiting Sheffield, United Kingdom, S10 2TH Principal Investigator: Katharine Patrick Collapse <<
  NCT02439957	Compare Efficacy of BCV to vGC... more >>V for Prevention of CMV Disease in Kidney Transplant Recipients Who Are CMV Seropositive Pretransplant Collapse <<	Phase 3	Terminated	-	United States, California ... more >> St. Vincent Medical Center Los Angeles, California, United States, 90057 United States, Colorado University of Colorado Hospital/Health Science Center Aurora, Colorado, United States, 80045 United States, Connecticut Yale New Haven Hospital New Haven, Connecticut, United States, 06520 Collapse <<
  NCT03532035	Adenovirus	Phase 2	Not yet recruiting	December 20, 2019	-

• 更多
• 参考文献

• [1] Quenelle DC, Lampert B, et al. Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. J Infect Dis. 2010 Nov 15;202(10):1492-9.

  [2] Parker S, Touchette E, et al. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res. 2008 Jan;77(1):39-49.